These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 28012118)

  • 1. Risk factors for QTc-prolongation: systematic review of the evidence.
    Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
    Int J Clin Pharm; 2017 Feb; 39(1):16-25. PubMed ID: 28012118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
    Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
    Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review.
    Tomaselli Muensterman E; Tisdale JE
    Pharmacotherapy; 2018 Aug; 38(8):813-821. PubMed ID: 29882591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and determinants of QT interval prolongation in medical inpatients.
    Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
    Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative torsade de pointes: a systematic review of published case reports.
    Johnston J; Pal S; Nagele P
    Anesth Analg; 2013 Sep; 117(3):559-564. PubMed ID: 23744954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
    Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
    Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Management of Hospitalized Psychiatric Patients Taking Multiple QTc-Prolonging Drugs.
    Vandael E; Vandenberk B; Willems R; Reyntens J; Vandenberghe J; Foulon V
    J Clin Psychopharmacol; 2017 Oct; 37(5):540-545. PubMed ID: 28817488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
    Vandael E; De WuLf I; Foulon V
    J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study.
    Ali Z; Ismail M; Nazar Z; Khan F; Khan Q; Noor S
    BMC Psychiatry; 2020 Jun; 20(1):277. PubMed ID: 32493330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a risk score for QTc-prolongation: the RISQ-PATH study.
    Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
    Int J Clin Pharm; 2017 Apr; 39(2):424-432. PubMed ID: 28281228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
    Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Torsade de Pointes in a tertiary hospital population.
    Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V
    Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
    Glassman AH; Bigger JT
    Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Induced QTc Prolongation: What We Know and Where We Are Going.
    Mangona E; Sandonato E; Brothers TN; Pawasauskas J
    Curr Drug Saf; 2022; 17(2):100-113. PubMed ID: 34551700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.